865,400 Shares in BiomX Inc. (NYSEMKT:PHGE) Purchased by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. acquired a new stake in shares of BiomX Inc. (NYSEMKT:PHGE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 865,400 shares of the company’s stock, valued at approximately $632,000. Alyeska Investment Group L.P. owned about 4.76% of BiomX as of its most recent SEC filing.

Separately, Allostery Investments LP bought a new position in shares of BiomX in the fourth quarter worth $470,000. 40.57% of the stock is owned by hedge funds and other institutional investors.

BiomX Price Performance

Shares of BiomX stock opened at $0.55 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. BiomX Inc. has a one year low of $0.48 and a one year high of $4.90. The business’s 50 day simple moving average is $0.58 and its two-hundred day simple moving average is $0.68. The stock has a market capitalization of $13.62 million, a P/E ratio of -0.73 and a beta of 1.51.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of BiomX in a research note on Friday, April 4th.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.